Protagonist Therapeutics, Inc

PTGX Nasdaq SEC CIK 1377121
Follow Protagonist Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $274.4M +5723.6% vs same quarter last year
Net income $220M +659.3% vs same quarter last year
EPS, diluted $3.07 +595.2% vs same quarter last year
Operating cash flow −$23.2M −1098.8% vs same quarter last year
Revenue by quarter
$170.6M
$28.3M
$5.5M
$4.7M
$7.4M
$56.4M
$213.5M
$274.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$46M−$130.1M
FY24$434.4M$275.2M
FY23$60M−$79M
FY22$26.6M−$127.4M
FY21$27.4M−$125.6M
FY20$28.6M−$66.2M
FY19$231K−$77.2M
FY18$30.9M−$38.9M
FY17$20.1M−$37M
FY16-−$37.2M
FY15-−$14.9M
FY14-−$11.1M
FY13--
MarginsShare of revenue
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−343.6%−282.8%
FY2458.2%63.3%
FY23−156.1%−131.6%
FY22−494.2%−479.3%
FY21−460%−458.9%
FY20−225.4%−231.1%
FY19−34857.6%−33414.3%
FY18−136.7%−125.9%
FY17−188.9%−184.2%
FY16--
FY15--
FY14--
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$56.1M
FY24$182.8M
FY23−$70.8M
FY22−$108.9M
FY21−$109M
FY20−$73M
FY19−$42.5M
FY18−$50.4M
FY17$3.2M
FY16−$30.3M
FY15−$14.8M
FY14−$8M
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Protagonist Therapeutics
  • Healthcare median
−40000%−30000%−20000%−10000%0%10000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearProtagonist TherapeuticsHealthcare median
FY25−282.8%−30.6%
FY2463.3%−47%
FY23−131.6%−58%
FY22−479.3%−80.4%
FY21−458.9%−71.9%
FY20−231.1%−62.2%
FY19−33414.3%−46.3%
FY18−125.9%−49.6%
FY17−184.2%−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%